Viking Therapeutics, Inc. (NASDAQ:VKTX), a biopharmaceutical company based in San Diego, California, is set to participate in two major investor conferences in April 2026. The first is the Raymond James Biotech/BioPharma Conference on April 14 in New York, NY, followed by the Piper Sandler Spring Biopharma Symposium on April 16 in Boston, MA. At these events, Viking's management will engage in one-on-one meetings with potential investors to discuss their innovative therapies aimed at metabolic and endocrine disorders.

Viking's clinical pipeline includes VK2735, a dual agonist targeting glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, currently in Phase 3 trials for obesity. Additionally, VK2809 is being developed for lipid and metabolic disorders, having met primary and secondary endpoints in a Phase 2b study for non-alcoholic steatohepatitis (NASH). The company is also exploring VK0214 for X-linked adrenoleukodystrophy (X-ALD), which has shown safety and efficacy in early trials. Viking Therapeutics aims to leverage its expertise in metabolism to create impactful therapies that enhance patient health.